ArticleAddiction (Abingdon, England)2021
Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?
Article in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Safety of Stimulants Across Patient Populations: A Meta-Analysis.JAMA network open · 2025Pooled it
- Vitamin D's Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [Biological psychiatry · 2025Trial
- The role of Iowa gambling task performance in response to citalopram treatment for cocaine use disorder.The American journal of drug and alcohol abuse · 2025Trial
- Barriers and facilitators to medication-assisted treatment for cocaine use disorder among men who have sex with men: a qualitative study.Addiction science & clinical practice · 2024Trial
- Examining cocaine use reductions and long-term outcomes in two clinical trials of continuing care for cocaine dependence.Journal of substance use and addiction treatment · 2024Trial
- Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.Drug and alcohol dependence · 2021Trial
- A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis.Drug and alcohol dependence · 2021Trial
- Cocaine Use Disorder: Neuropathology and Exploratory Treatments.Molecular neurobiology · 2026Review
- Sex-specific differences in endocannabinoid regulation of cocaine-evoked dopamine in the medial nucleus accumbens shell.bioRxiv : the preprint server for biology · 2026Article
- A single extinction-based treatment with N-Acetylcysteine produces long-term reduction in cocaine relapse.Translational psychiatry · 2026Article
- Association between venlafaxine use and the risk of withdrawal from nonopioid substances: a nationwide, population-based study.Harm reduction journal · 2026Article
- C57 and DBA mouse strains express distinct cocaine avoidance phenotypes in an operant runway independent of differences in striatal dynorphin-enkephalin balance.Psychopharmacology · 2026Article
- GPR4 regulates temporally dynamic and sex-dependent cocaine-induced locomotor sensitization.Frontiers in molecular neuroscience · 2026Article
- Interest in contingency management and reducing stimulant use among syringe service program participants.Journal of substance use and addiction treatment · 2025Article
- Shifted Balance Between Ventral Striatal Prodynorphin and Proenkephalin Biases Development of Cocaine Place Avoidance.Addiction biology · 2025Article
- IL-6 Expression and the Confidence Interval-Based Estimation of Relevance (CIBER) Help Identify Persistent Inflammation and Cognitive Parameters of Executive Dysfunction in the Withdrawal Phase of Male Polydrug Abusers.Healthcare (Basel, Switzerland) · 2025Article
- Animal models of cocaine use: importance of social context and co-use.Trends in pharmacological sciences · 2025Review
- The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.Expert opinion on pharmacotherapy · 2025Review
- Systematic Review of Cocaine-Treatment Interventions for Black Americans.Clinical psychological science : a journal of the Association for Psychological Science · 2025Article
- Digitally delivered contingency management during methadone treatment for people with co-occurring cocaine and opioid use: a protocol for a randomized controlled trial.Frontiers in psychiatry · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCocaine use contines to be a significant public health problem world-wide. However, despite substantial research efforts, no pharmacotherapies are approved for the treatment of cocaine use disorder (CUD). ARGUMENT: Studies have identified positive signals for a range of medications for treating CUD. These include long-acting amphetamine formulations, modafinil, topiramate, doxazosin and combined topiramate and mixed amphetamine salts extended-release (MAS-ER). However, valid conclusions about a medication's clinical efficacy require nuanced approaches that take into account behavioural phenotypes of the target population (frequency of use, co-abuse of cocaine and other substances, genetic subgroups, psychiatric comorbidity), variables related to the medication (dose, short-/long-acting formulations, titration speed, medication adherence) and other factors that may affect treatment outcomes. Meta-analyses frequently do not account for these co-varying factors, which contributes to a somewhat nihilistic view on pharmacotherapeutic options for CUD. In addition, the predominant focus on abstinence, which is difficult for most patients to achieve, may overshadow more nuanced therapeutic signals.
conclusionWhile there is an emphasis on finding new medications with novel mechanisms of action for treating CUD, currently available medications deserve further investigation based on the existing literature. Evaluating refined metrics of treatment success in well-defined subgroups of patients, and further exploring combination therapies and their synergy with behavioural/psychosocial interventions, are promising avenues to establishing effective therapies for CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.